A meta-analysis of nucleos(t)ide analogues in patients with decompensated cirrhosis due to hepatitis B

Digestive Diseases and Sciences

Volumn 58, Issue 3, 2013, Pages 815-823

  Huang, Yingnan ^a   Wu, Hao ^a   Wu, Shengdi ^a   Fu, Da ^a   Ma, Yushui ^a   Shen, Xizhong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Chronic; Decompensated; Hepatitis B; Liver cirrhosis; Nucleos(t)ide analogues

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; TELBIVUDINE; TENOFOVIR;

ARTICLE; CHILD TURCOTTE PUGH SCORE; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; DRUG EFFECT; HEPATITIS B; HUMAN; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SEROCONVERSION;

ANTIVIRAL AGENTS; HEPATITIS B; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; NUCLEOSIDES; NUCLEOTIDES; REVERSE TRANSCRIPTASE INHIBITORS; THYMIDINE;

EID: 84876679058     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2414-y     Document Type: Article

References (26)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-242.
2. Cárdenas A, dGinès P. Management of patients with cirrhosis awaiting liver transplantation. Gut. 2011;60:412-421.
3. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-686.
4. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006;101:1797-1803.
5. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61-68.
6. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256-1263.
7. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743-1751.
8. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886-893.
9. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53:348-356.
10. Zhang QQ, An X, Liu YH, et al. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J. 2011;8:72.
11. Cochrane Library. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Available at: http://www.cochrane-handbook.org/. Accessed 20.07.11.
12. Cai ZF, Shang FM, Zhao WX, Lü F, Zhang Z. A clinical study on lamivudine treatment for decompensated cirrhosis due to hepatitis B. J Xi'an Jiaotong Univ (Med Sci). 2006;27:575-577.
13. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology. 2001;34:411-416.
14. Li CZ, Li TG, Gan XM Liu ZB. Clinical study on the treatment of 38 cases of decompensation liver cirrhosis by lamivudine. Chin J Infect Control. 2007;6:319-322.
15. Manolakopoulos S, Karatapanis S, Elefsiniotis J, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol. 2004;99:57-63.
16. Park TW, Park YM, Bae SH, et al. Efficacy and safety of long-term lamivudine therapy in the patients with decompensated liver cirrhosis secondary to hepatitis B. Taehan Kan Hakhoe Chi. 2002;8:428-435.
17. Wang JF, Zhang WJ, Wu ZC, Wang MT. Clinical course of lamivudine in 56 patients with decompensated cirrhosis. Chin Rem Clin. 2006;6:547-548.
18. Wu HY, You DH. The efficacy of two-year's telbivudine therapy on decompensated hepatitis B cirrhosis documentation. J Clin Hepatol. 2010;26:605-607.
19. Zhu GB. The efficacy of telbivudine therapy on decompensated hepatitis B cirrhosis documentation. Chin J Trauma Disabil Med. 2009;17:95-96.
20. Hann HW, Fontana RJ, Wright T, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl. 2003;9:49-56.
21. Fontana RJ, Keeffe EB, Carey W, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl. 2002;8:433-439.
22. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36:687-696.
23. Gane EJ, Wang Y, Liaw YF, et al. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int. 2011;31:676-684.
24. Kim YJ, Cho HC, Sinn DH, et al. Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. J Gastroenterol Hepatol. 2012;27:306-312.
25. Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology. 2002;123:719-727.
26. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408-412.